Administering G-CSF also had an effect on patients experiencing a treatment delay; there was a 60% reduction in the number of patients experiencing a treatment delay for any reason (relative risk 0.40, P<0.001) and an 80% reduction in the number of patients whose delay was due to neutropenia (relative risk 0.20, P<0.001). Here, CSF3 is linked to neutropenia.